GlassScriptPhysician profile
Diane Daras
NPI 1992381065
$2,781.59
in general payments reported to CMS, 2019-2025
17 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $163 · 2024: $2,511 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,607 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,606.77 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $406.15 | 2024 | Caplyta |
| Alkermes, INC. | $316.00 | 2024 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $308.89 | 2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $280.05 | 2024-2025 | Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $252.90 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $231.46 | 2024 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.98 | 2022-2024 | Relistor |
| Vanda Pharmaceuticals INC. | $160.61 | 2024 | Fanapt |
| Almatica Pharma LLC | $146.03 | 2024 | Loreev Xr, Teriparatide |
| E.R. Squibb & Sons, L.L.C. | $113.85 | 2024-2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $108.82 | 2022 | |
| Abbvie INC. | $95.41 | 2024 | |
| Protega Pharmaceutials INC | $92.51 | 2024 | Roxybond |
| Forte Bio-Pharma LLC | $42.20 | 2024 | Prolate, Nalocet |
| Takeda Pharmaceuticals U.S.A., INC. | $25.29 | 2024 | Trintellix |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $19.66 | 2024 | Rexulti |
| Azurity Pharmaceuticals, INC. | $13.78 | 2024 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Daras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.